Key Insights• The China biosurgery market represents one of the largest and fastest-growing national markets for surgical biomaterials globally. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The China biosurgery market is distinguished by its vast healthcare system, enormous surgical volumes, and rapid technological advancement. According to the 2025 China Health Statistics Yearbook, 97.68 million inpatient surgical procedures were performed in China in 2024, representing a consistent year-on-year increase. Total health expenditure in China reached approximately 9.2 trillion yuan in 2025, representing 6.8% of GDP. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the rapid expansion of high-tech medical care, the acceleration of domestic substitution in medical devices, and the implementation of volume-based procurement policies.• China's healthcare system performed 97.68 million inpatient surgical procedures in 2024, reflecting the country's immense surgical volume and providing a robust foundation for biosurgical product demand. Total health expenditure reached 9.2 trillion yuan in 2025 (6.8% of GDP).Bone-Graft Substitutes represent the largest product category within the Chinese biosurgery market, driven by the high volume of orthopedic procedures.

China's orthopedic surgery volume reached approximately 5 million procedures in 2025, growing at a CAGR of approximately 10%.• China's aging population represents a significant long-term demand driver. As of 2025, 323.38 million people (23.0% of the population) were aged 60 years or older, with 223.65 million (15.9%) aged 65 or older. The regulatory environment, centered on the National Medical Products Administration (NMPA), is undergoing significant modernization. In 2025, the NMPA approved 104 medical devices to enter the innovative medical device special review process and registered 308 medical device products in March 2025 alone.Market Outlook• According to the research report, "China Biosurgery Market Overview, 2031 Overview, 2031," published by Actual Market Research, the China Biosurgery market is anticipated to grow at more than 6.51% CAGR from 2026 to 2031.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. China's medical device industry is experiencing rapid growth, with the government actively supporting innovation in high-end medical devices through policy measures including the "Optimizing Whole Life-Cycle Regulation in Support of the Innovative Development of High-End Medical Devices" (Announcement No. 63, 2025).• Rising surgical procedures and expanding high-tech medical care are key drivers propelling market expansion. With 97.68 million inpatient surgical procedures performed in 2024, China's surgical volume continues to grow consistently.

The rapid expansion of high-tech medical care, including robotic-assisted surgery and minimally invasive techniques, creates sustained demand for advanced biosurgical products.Market DynamicsDriver: Massive and Growing Surgical Volumes Across All SpecialtiesChina performs tens of millions of surgical procedures annually across its vast network of hospitals and healthcare facilities. According to the 2025 China Health Statistics Yearbook, 97.68 million inpatient surgical procedures were performed in 2024, representing a consistent year-on-year increase. Orthopedic surgery volume reached approximately 5 million procedures in 2025, growing at a CAGR of approximately 10% from 2010. Cardiovascular procedures are also expanding rapidly, with coronary stent procedures expected to reach 2.5 million in 2025 (34% of global volume). The breadth and depth of surgical activity in China ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. Total health expenditure of 9.2 trillion yuan (6.8% of GDP) provides substantial financial resources to support expanding surgical volumes.

The continued expansion of surgical capacity, driven by hospital modernization and the growing network of healthcare facilities, further reinforces this demand driver.Challenge: Volume-Based Procurement and Pricing PressureDespite the market's enormous size and growth potential, biosurgery manufacturers face significant challenges from China's volume-based procurement (VBP) policies. The national centralized drug and medical device procurement program, which began in 2018, has been extended to cover high-value medical consumables including orthopedic implants, cardiovascular stents, and other surgical products. The VBP policy has led to dramatic price reductions in many cases exceeding 80% for selected products, compressing profit margins for both domestic and international manufacturers. Additionally, the NMPA's regulatory framework is becoming increasingly stringent, with the 2025 revised Medical Device Supervision and Administration Regulations (effective January 20, 2025) requiring registrants and filing entities to assume full lifecycle quality management responsibility. Manufacturers must continually demonstrate both clinical efficacy and cost-effectiveness while navigating an increasingly complex regulatory and pricing environment.Trend: Accelerating Domestic Substitution and Local ManufacturingThe Chinese biosurgery market is experiencing a significant transformation driven by government policies promoting domestic substitution in medical devices. The NMPA's Announcement No. 30 (2025), issued on March 18, 2025, further optimizes requirements for the domestic production of imported medical devices, supporting foreign-invested enterprises in localizing production of high-end medical equipment.

In 2025, the NMPA registered 3,400 medical device names, with approximately 40% developed and produced in China. The innovative medical device special review process approved 104 devices in 2025, reflecting the government's commitment to accelerating the market entry of domestically developed innovative products. Domestic manufacturers are rapidly gaining market share across multiple biosurgery product categories, with the number of registered Chinese medical devices increasing and high-tech device registrations growing. Companies such as Suzhou Huihan Medical Technology and Shenzhen Sino Biomedical are developing innovative products that challenge international market leaders.Policies• The National Medical Products Administration (NMPA) serves as the primary regulatory authority for medical devices in China. In 2025, the NMPA registered 308 medical device products in March alone and continued to implement the 2025 revised Medical Device Supervision and Administration Regulations.• The 2025 revised Medical Device Supervision and Administration Regulations (effective January 20, 2025) require registrants and filing entities to assume full lifecycle quality management responsibility and strengthen requirements for registration application documentation.• The Innovative Medical Device Special Review Process continues to accelerate market access for novel technologies. In 2025, the NMPA received 457 innovative medical device special review applications, with 104 approved to enter the special review process.

The Priority Review Catalog for High-End Medical Devices (2025 Edition) was released by the NMPA on December 26, 2025, prioritizing high-end medical devices including those incorporating new materials and new technologies.• The NMPA's Announcement No. 63 (2025) on "Optimizing Whole Life-Cycle Regulation in Support of the Innovative Development of High-End Medical Devices" focuses on medical robots, high-end imaging equipment, AI medical devices, and new biomaterial medical devices.• Volume-based procurement (VBP) policies continue to shape the medical device market. The centralized procurement program has been extended to cover high-value medical consumables including orthopedic implants, dramatically reducing prices and reshaping competitive dynamics across the biosurgery market.Segment AnalysisChina Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the Chinese biosurgery market, driven by the high volume of orthopedic procedures. China's orthopedic surgery volume reached approximately 5 million procedures in 2025, growing at a CAGR of approximately 10% from 2010. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging Chinese population with 23.0% aged 60 and older continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding.

The Chinese absorbable hemostatic materials market grew from 28 billion yuan in 2020 to 40 billion yuan in 2024, at a CAGR of approximately 9.33%. Domestic manufacturers are developing innovative products, including Shenzhen Sino Biomedical's "absorbable hemostatic fluid gel" which received NMPA Class III medical device registration in 2025.• Surgical Sealants and Adhesives represent the fastest-growing product category in the Chinese biosurgery market, driven by increasing adoption of minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The Chinese surgical sealants and hemostatic agents market was valued at 93 billion yuan in 2024, growing at a CAGR of 7.9% from 2020 to 2024.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Chinese hospitals.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage.

The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.China Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in China, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. Orthopedic surgery volume reached approximately 5 million procedures in 2025, growing at a CAGR of approximately 10% from 2010. The aging population with 223.65 million aged 65 and older continues to drive demand for musculoskeletal interventions.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. With 97.68 million inpatient surgical procedures performed in 2024, general surgery represents a substantial volume driver.• Cardiovascular Surgery represents the fastest-growing application area in the Chinese biosurgery market, driven by the high prevalence of cardiovascular disease. China has over 330 million cardiovascular disease patients.

Coronary stent procedures are expected to reach 2.5 million in 2025 (34% of global volume), while cardiac electrophysiology procedures are projected to reach 575,000 in 2025, growing at a CAGR of 28.0% from 2020 to 2025.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks. In 2025, the neurosurgery department at Xuanwu Hospital performed over 20,000 surgeries. With surgical robot penetration increasing and the adoption of advanced techniques, neurosurgery is one of the fastest-growing surgical specialties in China.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.China Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the Chinese biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The NMPA's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Chinese market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats.

Domestic manufacturers are actively developing synthetic alternatives, with innovative products such as "magnesium-containing biodegradable bone repair materials" receiving NMPA approval.China Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in China, accounting for the majority of revenue. With 97.68 million inpatient surgical procedures performed in 2024, hospitals are the primary setting for biosurgical product utilization. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary channel for biosurgical product distribution.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Chinese biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.China Biosurgery Market Economics• The Chinese biosurgery market operates within a rapidly expanding healthcare system shaped by government investment, centralized procurement, and increasing domestic manufacturing. Healthcare expenditure reached approximately 9.2 trillion yuan in 2025, representing 6.8% of GDP. However, volume-based procurement (VBP) has created significant pricing pressure, with price reductions exceeding 80% for selected high-value medical consumables.

The National Healthcare Security Administration oversees reimbursement policies, while centralized and provincial procurement increasingly influence market access. Manufacturers must therefore balance clinical value and innovation with aggressive pricing requirements to remain competitive.• Procurement is conducted through provincial tenders, hospital-level agreements, and surgeon preferences, while consolidation has intensified competition across biosurgical product categories. China’s supply chain is also undergoing major transformation through domestic substitution policies and NMPA initiatives supporting localized manufacturing. Approximately 40% of registered medical devices in 2025 were domestically developed and produced. The country’s extensive hospital and surgical infrastructure continues to expand, particularly through tier-2 and tier-3 hospitals in less-developed regions. Implantable medical device procurement increased 31% year-on-year in 2023, demonstrating strong underlying demand.• China has a large and expanding surgical workforce supported by professional organizations, academic institutions, and ongoing specialist training.

Innovation investment is strongly driven by government initiatives focused on “new quality productive forces,” particularly medical robots, advanced imaging, AI-enabled devices, and biomaterial technologies. In 2025, the NMPA approved 104 devices for its innovative medical device special review process. Regulatory reforms, including the revised Medical Device Supervision and Administration Regulations effective January 2025, strengthen lifecycle quality requirements while streamlining pathways for innovative products and prioritizing high-end domestic technologies.• Technology adoption is advancing rapidly across robotic-assisted surgery, minimally invasive procedures, and advanced biomaterials. Chinese public hospitals procured 84 robotic surgical systems in 2025, with an average winning bid of approximately 8.47 million yuan per system. Long-term growth is supported by an aging population, with 323.38 million people aged 60 and above, alongside expanding healthcare infrastructure and substantial government investment. The China biosurgery market is anticipated to grow at more than 6.51% CAGR from 2026 to 2031.

Manufacturers that establish local capabilities, navigate VBP pricing pressures, and align with domestic innovation priorities are positioned to capture significant opportunities.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.